CTOs on the Move

Primmune Therapeutics

www.primmunerx.com

 
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.primmunerx.com
  • JLABS San Diego 3210 Merryfield Road
    San Diego, CA USA 92121
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Primmune Therapeutics raised $27.4M on 10/27/2020

Similar Companies

Adverum

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.

iCyt Mission Technology

iCyt Mission Technology is a Champaign, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Teva parenteral Medicines

Teva parenteral Medicines is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMx

BioMx is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biohaven Pharmaceutical

Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc.